anti-B-cell maturation antigen
J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
CSL’s Privigen approved as measles treatment by European Commission
Cases of measles have been rising in Europe since 2023
Legend Biotech appoints new group of scientific advisors
The company is focused on CAR-T cell therapy to treat multiple myeloma
Bristol Myers Squibb evolves and expands multiple myeloma programme
Created in 2016, the Standing in the Gaap programme aims to advance more equitable care
Gilead to acquire Arcellx in deal worth $7.8bn
The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma
Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma
Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable
J&J receives positive NICE recommendation for multiple myeloma treatment
The treatment is approved for use within the NHS in England and Wales
Johnson & Jonson secures FDA approval for multiple myeloma treatment
Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results
GSK’s Blenrep approved by FDA for multiple myeloma
Approval supported by positive results from phase 3 trial
BMS, Macmillan and 11 NHS Trusts publish report on cancer treatment prehabilitation
The report shows how prehabilitation can improve patient experience while alleviating capacity pressures